.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Cantor Fitzgerald
QuintilesIMS
Colorcon
Healthtrust
Johnson and Johnson
Covington
McKesson
Baxter

Generated: June 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,072,742

« Back to Dashboard

Claims for Patent: 9,072,742

Title:Method of predicting a predisposition to QT prolongation
Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Inventor(s): Lavedan; Christian (Potomac, MD), Volpi; Simona (Derwood, MD), Licamele; Louis (Gaithersburg, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:13/263,077
Patent Claims: 1. A method of administering iloperidone or a metabolite thereof to a human individual, the method comprising: determining or having determined the individual's BAI3 gene sequence at the rs1083338 locus; and in the case that the individual's BAI3 gene sequence at the rs1083338 locus is GG, administering to the individual a first quantity of iloperidone or a metabolite thereof, and in the case that the individual's BAI3 gene sequence at the rs1083338 locus is non-GG, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity.

2. The method of claim 1, further comprising: determining the individual's CYP2D6 genotype.

3. The method of claim 1, wherein the method comprises administering iloperidone to the human individual.

4. The method of claim 1, wherein the method comprises administering a metabolite of iloperidone to the human individual, wherein the metabolite is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-m- ethoxyphenyl]ethanol.

5. A method of administering a compound that is iloperidone or a metabolite thereof to a human individual suffering from long QT syndrome (LQTS), the method comprising: determining or having determined the individual's BAI3 gene sequence at the rs1083338 locus; and administering to the individual either a first quantity or a second quantity of the compound based on the individual's BAI3 gene sequence at the rs1083338 locus, wherein the second quantity is larger than the first quantity, and wherein the first quantity is administered to the individual if the individual has a GG genotype at the rs1083338 locus, and wherein the second quantity is administered to the individual if the individual has a genotype at the rs1083338 locus that is non-GG.

6. The method of claim 5, further comprising: determining the individual's CYP2D6 genotype.

7. The method of claim 5, wherein the compound is iloperidone.

8. The method of claim 5, wherein the compound is a metabolite of iloperidone, and is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-meth- oxyphenyl]ethanol.

9. The method of claim 3, wherein the second quantity of iloperidone is 24 mg/day.

10. The method of claim 7, wherein the second quantity of iloperidone is 24 mg/day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Moodys
Johnson and Johnson
Fuji
QuintilesIMS
Teva
US Army
Cantor Fitzgerald
Farmers Insurance
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot